Candel Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Candel Therapeutics Depreciation & Amortization Growth & History (CADL)
Candel Therapeutics's depreciation and amortization was $845,000 for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $845,000 | −$145,000 | −14.65% |
| 2024 | 2024-12-31 | $990,000 | $30,000 | +3.13% |
| 2023 | 2023-12-31 | $960,000 | $182,000 | +23.39% |
| 2022 | 2022-12-31 | $778,000 | $546,000 | +235.34% |
| 2021 | 2021-12-31 | $232,000 | $141,000 | +154.95% |
| 2020 | 2020-12-31 | $91,000 | — | — |
Candel Therapeutics quarterly depreciation and amortization
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $200,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $149,000 | −$96,000 | −39.18% |
| Q4 2025 | 2025-12-31 | $163,000 | — | — |
| Q3 2025 | 2025-09-30 | $200,000 | $0 | 0.00% |
| Q2 2025 | 2025-06-30 | $200,000 | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $245,000 | −$6,000 | −2.39% |
| Q3 2024 | 2024-09-30 | $200,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $200,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $251,000 | $21,000 | +9.13% |
| Q3 2023 | 2023-09-30 | $200,000 | $0 | 0.00% |
| Q2 2023 | 2023-06-30 | $200,000 | $0 | 0.00% |
| Q1 2023 | 2023-03-31 | $230,000 | $65,000 | +39.39% |
| Q3 2022 | 2022-09-30 | $200,000 | $178,000 | +809.09% |
| Q2 2022 | 2022-06-30 | $200,000 | $193,000 | +2757.14% |
| Q1 2022 | 2022-03-31 | $165,000 | $139,000 | +534.62% |
| Q3 2021 | 2021-09-30 | $22,000 | −$22,000 | −50.00% |
| Q2 2021 | 2021-06-30 | $7,000 | −$15,000 | −68.18% |
| Q1 2021 | 2021-03-31 | $26,000 | — | — |
| Q3 2020 | 2020-09-30 | $44,000 | — | — |
| Q2 2020 | 2020-06-30 | $22,000 | — | — |
Candel Therapeutics depreciation and amortization trends
Over the last five fiscal years, Candel Therapeutics's depreciation and amortization increased from $91,000 to $845,000, a change of $754,000. The latest reported quarter, Q2 2026, shows $200,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗